Insight Molecular Diagnostics Inc.
For the period ended Sep 30, 2025. Filed Nov 10, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 10, 2025
IMDX$2.47-1.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Net loss | $(10,854) | $(13,493) | $(27,267) | $(27,152) |
| Foreign currency translation adjustments | 1 | 20 | 65 | 8 |
| Comprehensive loss | $(10,853) | $(13,473) | $(27,202) | $(27,144) |
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SERIES A REDEEMABLE CONVERTIBLE PREFERRED STOCK AND SHAREHOLDERS’
EQUITY (DEFICIT)
| Series A RedeemableConvertible PreferredStock · Common Stock · AccumulatedOtherComprehensive · Accumulated · TotalShareholders’ | |||||||
|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Income | Deficit | Equity (Deficit) | |
| Balance at June 30, 2025 | — | $— | 28,617 | $367,965 | $85 | $(366,952) | $1,098 |
| Net Loss | — | — | — | — | — | (10,854) | (10,854) |
| Foreign currency translation adjustment | — | — | — | — | 1 | — | 1 |
| Stock-based compensation | — | — | — | 521 | — | — | 521 |
| Vesting of bonus awards | — | — | — | 14 | — | — | 14 |
| Shares issued for consultant services | — | — | 8 | 24 | — | — | 24 |
| Balance at September 30, 2025 | — | $— | 28,625 | $368,524 | $86 | $(377,806) | $(9,196) |
| Series A RedeemableConvertible PreferredStock · Common Stock · AccumulatedOtherComprehensive · Accumulated · TotalShareholders’ | |||||||
|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Income | Deficit | Equity | |
| Balance at June 30, 2024 | — | $— | 13,368 | $326,201 | $37 | $(303,535) | $22,703 |
| Net Loss | — | — | — | — | — | (13,493) | (13,493) |
| Foreign currency translation adjustment | — | — | — | — | 20 | — | 20 |
| Stock-based compensation | — | — | — | 450 | — | — | 450 |
| Vesting of bonus awards | — | — | — | 14 | — | — | 14 |
| Sale of common shares under at-the-market transactions, net of financing costs | — | — | 6 | 17 | — | — | 17 |
| Balance at September 30, 2024 | — | $— | 13,374 | $326,682 | $57 | $(317,028) | $9,711 |
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SERIES A REDEEMABLE CONVERTIBLE PREFERRED STOCK AND SHAREHOLDERS’ (DEFICIT) EQUITY
| Series A RedeemableConvertible PreferredStock · Common Stock · AccumulatedOtherComprehensive · Accumulated · TotalShareholders’ | |||||||
|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Income | Deficit | Deficit | |
| Balance at December 31, 2024 | — | $— | 17,453 | $338,244 | $21 | $(350,539) | $(12,274) |
| Net Loss | — | — | — | — | — | (27,267) | (27,267) |
| Foreign currency translation adjustment | — | — | — | — | 65 | — | 65 |
| Stock-based compensation | — | — | — | 1,498 | — | — | 1,498 |
| Vesting of bonus awards | — | — | — | 42 | — | — | 42 |
| Sale of common shares, net of financing costs | — | — | 11,146 | 28,656 | — | — | 28,656 |
| Shares issued for consultant services | — | — | 26 | 84 | — | — | 84 |
| Balance at September 30, 2025 | — | $— | 28,625 | $368,524 | $86 | $(377,806) | $(9,196) |
| Series A RedeemableConvertible PreferredStock · Common Stock · AccumulatedOtherComprehensive · Accumulated · TotalShareholders’ | |||||||
|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Income | Deficit | Equity | |
| Balance at December 31, 2023 | 5 | $5,126 | 8,261 | $310,295 | $49 | $(289,876) | $20,468 |
| Net loss | — | — | — | — | — | (27,152) | (27,152) |
| Foreign currency translation adjustment | — | — | — | — | 8 | — | 8 |
| Stock-based compensation | — | — | — | 1,254 | — | — | 1,254 |
| Vesting of bonus awards | — | — | — | 38 | — | — | 38 |
| Sale of common shares, net of financing costs | — | — | 5,077 | 15,269 | — | — | 15,269 |
| Sale of common shares under at-the-market transactions, net of financing costs | — | — | 6 | 17 | — | — | 17 |
| Shares issued upon vesting of RSUs | — | — | 4 | — | — | — | — |
| Shares issued for consultant services | — | — | 26 | 72 | — | — | 72 |
| Redemption of Series A redeemable convertible preferred stock | (5) | (5,389) | — | — | — | — | — |
| Accretion of Series A convertible preferred stock to redemption value | — | 263 | — | (263) | — | — | (263) |
| Balance at September 30, 2024 | — | $— | 13,374 | $326,682 | $57 | $(317,028) | $9,711 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.